Frequency of ABCG2 421C>A Genetic Variant and The Efficiency of Treatment with Rosuvastatin in Kazakh Male Patients
| Autor: | Khassenbekova Zhr, Tuleutayeva Gk, Kakimova Ab, Ongarbayeva Ae, Urazova Ðs, Kozhakhmetova Ss, Nurgozhin ТS, Kozhakhmetov Ss, Sibagatova As, Kissikova Sl, Yakovenko Gi, Kushugulova Ar, Urazbayeva Gs, Beysembayeva Sch, Saduakhassova Sa |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
education.field_of_study
medicine.medical_specialty business.industry Therapeutic effect Metabolic disorder Population nutritional and metabolic diseases Kazakh Pharmacology medicine.disease Omics language.human_language Internal medicine Genotype medicine language Rosuvastatin Allele education business medicine.drug |
| Zdroj: | Journal of Molecular and Genetic Medicine. 10 |
| ISSN: | 1747-0862 |
| DOI: | 10.4172/1747-0862.1000225 |
| Popis: | Rosuvastatin is one of the most effective lipid-lowering drugs. Nevertheless its activity varies in different populations. Important role in this belongs to ABCG2. The objective of this study was to determine the impact of ABCG2 genotype on therapeutic effect of rosuvastatin in Kazakh population. This study included 82 Kazakh patients with metabolic disorder undergoing 10 -20 mg/day of rosuvastatin therapy for 12 weeks. Our findings indicated that people with 421AA genotype had higher response to the drug. The frequency of minor alleles in the studied group was 29.5%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|